PfizerLong
Will PFE take Another Run @ $62 ? Pool Guy Thinks So !
PFE had a nice reversal this week, putting in a nice hammer candle on the weekly, bouncing nicely off of the 2001 ATH.
For those with a high tolerance, I'd buy @ $47.50 with stop @ 10% lower. Another run at the all time high will bring us back to $62, or a gain of 30%. A low risk trade with a 3:1 reward if you use the price levels on the chart. Those with a lower risk tolerance would wait for confirmation with next week's weekly close.
On top of that - we should not forget that they have a product likely to be in high demand for some time - which is of course COVID vaccines - probably the only thing better than erectile dysfunction pills.
For those of you old enough to remember, Viagra was the drug that sent them to their 2001 ATH.
Find me a better product than COVID vaccines for a company to sell - the only thing better than penis pills or cigarettes !
PG
For those with a high tolerance, I'd buy @ $47.50 with stop @ 10% lower. Another run at the all time high will bring us back to $62, or a gain of 30%. A low risk trade with a 3:1 reward if you use the price levels on the chart. Those with a lower risk tolerance would wait for confirmation with next week's weekly close.
On top of that - we should not forget that they have a product likely to be in high demand for some time - which is of course COVID vaccines - probably the only thing better than erectile dysfunction pills.
For those of you old enough to remember, Viagra was the drug that sent them to their 2001 ATH.
Find me a better product than COVID vaccines for a company to sell - the only thing better than penis pills or cigarettes !
PG
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.